CSIMarket


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 
 

INBP's Revenue Growth by Quarter and Year

Integrated Biopharma Inc's Revenue results by quarter and year




INBP Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter June - 17.06 13.54 13.58
III Quarter March - 17.07 13.63 14.09
II Quarter December - 14.26 14.20 12.00
I Quarter September 12.75 15.17 11.41 10.30
FY   12.75 63.56 52.78 49.97



INBP Revenue first quarter 2021 Y/Y Growth Comment
Integrated Biopharma Inc reported decline in Revenue in the first quarter by -15.95% to $ 12.75 millions, from the same quarter in 2020.
The contraction in the first quarter Integrated Biopharma Inc's Revenue compares unfavorably to the Company's average Revenue growth of 1.98%.

Looking into first quarter results within Biotechnology & Pharmaceuticals industry 74 other companies have achieved higher Revenue growth. While Integrated Biopharma Inc' s Revenue fall of -15.95% ranks overall at the positon no. 2887 in the first quarter.




INBP Revenue ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter June - 26 % -0.29 % 8.04 %
III Quarter March - 25.24 % -3.26 % 33.18 %
II Quarter December - 0.42 % 18.33 % 11.11 %
I Quarter September -15.95 % 32.95 % 10.78 % 5.42 %
FY   - 20.42 % 5.62 % 14.3 %

Financial Statements
Integrated Biopharma Inc's first quarter 2021 Revenue $ 12.75 millions INBP's Income Statement
Integrated Biopharma Inc's first quarter 2020 Revenue $ 15.17 millions Quarterly INBP's Income Statement
New: More INBP's historic Revenue Growth >>


INBP Revenue (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter June - -0.06 % -0.66 % -3.62 %
III Quarter March - 19.71 % -4.01 % 17.42 %
II Quarter December - -6 % 24.45 % 16.5 %
I Quarter September -25.26 % 12.04 % -15.98 % -18.06 %
FY (Year on Year)   - 20.42 % 5.62 % 14.3 %




Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #75
Healthcare Sector #417
Overall #2887

Revenue Y/Y Growth Statistics
High Average Low
7.73 % 1.98 % -6.2 %
(Mar 31 2019)   (Sep 30 2017)
Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #75
Healthcare Sector #417
Overall #2887
Revenue Y/Y Growth Statistics
High Average Low
7.73 % 1.98 % -6.2 %
(Mar 31 2019)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Integrated Biopharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
24.47 % 1.66 % -25.25 %
(Dec 31 2019)  


INBP's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Integrated Biopharma Inc reported fall in Revenue from the previous quarter by -25.26% to $ 12.75 millions, from $ 17.06 millions declared a quarter before.

Albeit seasonal influence normally fuel I. Quarter 2021 Revenue, this clearly could not be sufficient to recover Biotechnology & Pharmaceuticals's company outcome, Autumn Walsh, an industry contributor situated in New York wrote.

Within Biotechnology & Pharmaceuticals industry 106 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 3308.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #107
Healthcare Sector #538
Overall #3308
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #107
Healthcare Sector #538
Overall #3308
Revenue Q/Q Growth Statistics
High Average Low
24.47 % 1.66 % -25.25 %
(Dec 31 2019)  


INBP's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Integrated Biopharma Inc realized fall in Revenue from the previous quarter by -25.26% to $ 12.75 millions, from $ 17.06 millions achived a quarter before.

Even seasonal factors could not recover the I. Quarter for the Integrated Biopharma Inc, Autumn Walsh, an industry contributor situated in New York pointed out, she detected additional challenges down the road for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 106 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 3308.


Integrated Biopharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
Cumulative Revenue 12 Months Ending $ 61.14 $ 63.56 $ 60.04 $ 56.60 $ 56.54
Y / Y Revenue Growth (TTM) 8.14 % 20.45 % 13.67 % 6.23 % 10.68 %
Year on Year Revenue Growth Overall Ranking # 1903 # 1120 # 1066 # 226 # 970
Seqeuential Revenue Change (TTM) -3.81 % 5.87 % 6.08 % 0.11 % 7.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 2887 # 1818 # 1133 # 414 # 666




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Integrated Biopharma Inc's cumulative twelve months Revenue were $ 61 millions, company would post below average annual Revenue growth of 7.14% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Integrated Biopharma Inc's Revenue growth from the 17.06% growth in Jun 30 2021.

In the Healthcare sector 289 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1120 to 1903.

Revenue TTM Q/Q Growth Statistics
High Average Low
7.73 %
1.98 %
-6.2 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 75
Healthcare Sector # 290
Overall # 1903

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
34.36 %
-10.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 75
Sector # 417
S&P 500 # 2887
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Integrated Biopharma Inc's cumulative twelve months Revenue were $ 61 millions, company would post below average annual Revenue growth of -10.42% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Integrated Biopharma Inc's Revenue growth from the 17.06% growth in Jun 30 2021.

In the Healthcare sector 289 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1120 to 1903.

Revenue TTM Q/Q Growth Statistics
High Average Low
7.73 %
1.98 %
-6.2 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 75
Healthcare Sector # 290
Overall # 1903

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
34.36 %
-10.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 75
Sector # 417
S&P 500 # 2887




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INBP's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for INBP's Competitors
Revenue Growth for Integrated Biopharma Inc's Suppliers
Revenue Growth for INBP's Customers

You may also want to know
INBP's Annual Growth Rates INBP's Profitability Ratios INBP's Asset Turnover Ratio INBP's Dividend Growth
INBP's Roe INBP's Valuation Ratios INBP's Financial Strength Ratios INBP's Dividend Payout Ratio
INBP's Roa INBP's Inventory Turnover Ratio INBP's Growth Rates INBP's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2021
Enanta Pharmaceuticals Inc-0.24%$ -0.237 millions
Zimmer Biomet Holdings Inc -0.27%$ -0.275 millions
Community Health Systems Inc -0.35%$ -0.352 millions
Quest Diagnostics Inc-0.43%$ -0.431 millions
Twinlab Consolidated Holdings Inc -0.54%$ -0.539 millions
Repro Med Systems Inc -0.65%$ -0.654 millions
Avanos Medical Inc -0.86%$ -0.862 millions
Cytomx Therapeutics Inc -1.13%$ -1.130 millions
Bausch Health Companies Inc -1.26%$ -1.263 millions
Xtant Medical Holdings Inc -1.71%$ -1.705 millions
Mimedx Group Inc -1.91%$ -1.911 millions
Clovis Oncology inc -2.21%$ -2.208 millions
Teva Pharmaceutical Industries Ltd-2.29%$ -2.288 millions
Aziyo Biologics inc -2.45%$ -2.455 millions
Alimera Sciences Inc -2.57%$ -2.566 millions
Nuwellis Inc -2.68%$ -2.679 millions
Pressure Biosciences Inc -2.90%$ -2.903 millions
Lifevantage Corp-2.92%$ -2.924 millions
Immunitybio inc -2.94%$ -2.941 millions
Fitlife Brands Inc -3.15%$ -3.149 millions
Luna Innovations Inc-3.43%$ -3.425 millions
Cardiovascular Systems Inc -3.59%$ -3.591 millions
Vyant Bio Inc -3.95%$ -3.954 millions
Hologic Inc-4.28%$ -4.279 millions
Supernus Pharmaceuticals inc -4.30%$ -4.300 millions
Procyon Corp-4.51%$ -4.515 millions
Healthcare Services Group Inc -4.67%$ -4.670 millions
Star Equity Holdings Inc -4.92%$ -4.922 millions
Ayala Pharmaceuticals Inc -5.02%$ -5.015 millions
Recro Pharma Inc -5.44%$ -5.444 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ENJY's Profile

Stock Price

ENJY's Financials

Business Description

Fundamentals

Charts & Quotes

ENJY's News

Suppliers

ENJY's Competitors

Customers & Markets

Economic Indicators

ENJY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071